Top Wall Street Forecasters Revamp Intuitive Surgical Expectations Ahead Of Q1 Earnings

Intuitive Surgical is expected to report Q1 EPS of $2.11 on revenue of $2.62 billion, up from $1.81 and $2.25 billion a year ago, respectively. The FDA also issued an early alert on March 18 regarding a potentially high-risk issue with the company’s stapling devices, adding a regulatory overhang ahead of earnings. Shares fell 0.8% to $465.60 on Monday.

Analysis

The setup into this print is less about the quarter and more about whether the franchise can keep compounding through a regulatory overhang. When a platform company with recurring consumables and installed-base economics gets a stapling-device alert right before earnings, the market usually discounts not just the direct product line but the broader quality-control narrative, which can compress the multiple even if the quarter itself is clean. That makes the next 1-2 trading sessions a volatility event, but the bigger question is whether management can isolate the issue quickly enough to prevent a second-order hit to procedure growth and capital equipment conversion over the next 1-2 quarters.

The deeper risk is not a one-time recall headline; it is hospital procurement behavior. If buyers start assuming incremental scrutiny on adjacent accessories, replacement cycles can elongate and purchasing committees may demand more evidence before approving expansions, which would pressure future utilization rather than current revenue. Competitively, that creates a narrow window for alternative surgical platforms and adjacent instruments suppliers to pitch reliability and redundancy, even if they are not yet in a position to take meaningful share at scale.

From a trading standpoint, the implied event risk looks asymmetric: the stock can gap down hard on any language suggesting breadth of the issue, but upside is capped unless management de-risks the regulatory story and reaffirms procedure momentum. The consensus seems to be treating the FDA alert as containable; the contrarian view is that the market may be underpricing the probability of a longer-duration narrative drag on multiple expansion. If the company delivers a beat with limited commentary on the alert, the stock can still rally, but the more durable move requires a clean path on guidance and no incremental product-safety escalation in the following weeks.

Key Decisions for Investors

• Buy near-dated ISRG put spreads into the print, targeting a 1-3 week horizon: limited premium outlay for protection against a headline-driven gap lower if management cannot ring-fence the FDA issue.
• If long ISRG for quality growth, hedge with a partial short in the same name via call overwrite or collar through the next 30-45 days; the risk/reward favors capping upside into an event with asymmetric downside tail risk.
• Pair trade: long a diversified medtech name with less regulatory binary risk and short ISRG for the next 1-2 quarters, betting that multiple compression from safety scrutiny outweighs any earnings beat.
• Do not add size until management clarifies scope and remediation path; if the company explicitly limits the alert to a narrow device subset and reaffirms procedure trends, the setup improves for a post-earnings re-rating over 4-8 weeks.